Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort

Cancer

Volumn 122, Issue 23, 2016, Pages 3673-3681

  Mai, Phuong L ^a   Best, Ana F ^a   Peters, June A ^a   DeCastro, Rosamma M ^a   Khincha, Payal P ^a   Loud, Jennifer T ^a   Bremer, Renée C ^a   Rosenberg, Philip S ^a   Savage, Sharon A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cumulative cancer risk; Li Fraumeni syndrome; second cancer; second cancer risk; TP53

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHOROID PLEXUS TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; OSTEOSARCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK MANAGEMENT; SECOND CANCER; SOFT TISSUE SARCOMA; BREAST TUMOR; CARCINOMA; CHILD; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GERMLINE MUTATION; INFANT; LI-FRAUMENI SYNDROME; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RISK; SARCOMA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADRENOCORTICAL CARCINOMA; ADULT; BREAST NEOPLASMS; CARCINOMA; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; INFANT; INFANT, NEWBORN; LI-FRAUMENI SYNDROME; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); PROSPECTIVE STUDIES; RISK; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES; YOUNG ADULT;

EID: 84994220077     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30248     Document Type: Article

References (35)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747–752.
2. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362.
3. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54:1298–1304.
4. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101–124.
5. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238.
6. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–749.
7. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21:313–320.
8. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–614.
9. Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46:689–693.
10. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38:43–47.
11. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27:e108–e109; author reply e110.
12. Bougeard G, Sesboue R, Baert-Desurmont S, et al; French LFS working group. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008;45:535–538.
13. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. 2012;11:607–613.
14. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed July 1, 2016.
15. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345–2352.
16. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–6650.
17. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–1256.
18. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83–87.
19. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47:421–428.
20. Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51:344–356.
21. Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66:8287–8292.
22. Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Hum Genet. 2011;130:789–794.
23. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72:975–983.
24. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–1270.
25. Doherty J, Bonadies DC, Matloff ET. Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. J Genet Couns. 2015;24:683–687.
26. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12:1339–1346.
27. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606–611.
28. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289–294.
29. Salmon A, Amikam D, Sodha N, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol). 2007;19:490–493.
30. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400–409.
31. Wang MC, Jewell NP, Tsai WY. Asymptotic properties of the product limit estimate under random truncation. Ann Stat. 1986;14:1597–1605.
32. Rosenberg PS. Hazard function estimation using B-splines. Biometrics. 1995;51:874–887.
33. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822–826.
34. R Core Team. R: a language and environment for statistical computing. https://www.R-project.org/. Accessed July 1, 2016.
35. Therneau T. A package for survival analysis in S. Version 2.38. http://CRAN.R-project.org/package=survival. Accessed July 1, 2016.